Allianz Asset Management GmbH cut its stake in AtriCure Inc. (NASDAQ:ATRC) by 17.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,782 shares of the medical device company’s stock after selling 32,865 shares during the period. Allianz Asset Management GmbH owned 0.44% of AtriCure worth $2,750,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in ATRC. Teacher Retirement System of Texas bought a new stake in AtriCure in the fourth quarter valued at approximately $203,000. Campbell & CO Investment Adviser LLC acquired a new position in AtriCure in the third quarter valued at approximately $205,000. Capital Fund Management S.A. lifted its stake in AtriCure by 57.3% in the fourth quarter. Capital Fund Management S.A. now owns 15,100 shares of the medical device company’s stock valued at $275,000 after buying an additional 5,500 shares during the period. OxFORD Asset Management LLP acquired a new position in AtriCure in the third quarter valued at approximately $457,000. Finally, JPMorgan Chase & Co. acquired a new position in AtriCure in the third quarter valued at approximately $771,000. Institutional investors and hedge funds own 87.50% of the company’s stock.
ATRC stock opened at $19.81 on Wednesday. AtriCure Inc. has a 12 month low of $14.88 and a 12 month high of $25.18. The company has a quick ratio of 1.87, a current ratio of 2.58 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $726.80, a P/E ratio of -23.87 and a beta of 0.30.
In other news, Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Justin J. Noznesky sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total value of $68,120.00. The disclosure for this sale can be found here. 11.90% of the stock is owned by corporate insiders.
ATRC has been the topic of several recent analyst reports. TheStreet lowered AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 price target on shares of AtriCure in a research note on Sunday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target (down from $25.00) on shares of AtriCure in a research note on Tuesday, January 16th. BidaskClub raised AtriCure from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 15th. Finally, Canaccord Genuity boosted their price target on AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. AtriCure currently has a consensus rating of “Buy” and a consensus target price of $24.80.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.